For the latest instalment of Sponsor Atlas: Discovering Biotech Startups, we're looking at Palo Alto's CiberMed Inc.
Happy December! In this edition of Sponsor Atlas: Discovering Biotech Startups, we're looking at Atherton, CA's Apricity Therapeutics!
In this edition of Discovering Biotech Startups, we're looking at San Francisco's Alaunus Biosciences
In the latest edition of Discovering Biotech Startups, we're looking at San Francisco's 712 North!
Next up in the Sponsor Atlas: Discovering Biotech Startups series is Palo Alto's Quartz Therapeutics!
In this edition of Sponsor Atlas: Discovering Biotech Startups, we're examining Westwood, MA's Abtelum Biomedical
In the latest edition of Sponsor Atlas: Discovering Biotech Startups, we're looking at Princeton, New Jersey's stealth biotech, KayoThera!
In this edition of Discovering Biotech Startups, we're looking at New York's Scopus Biopharma!
In the newest edition of Sponsor Atlas: Discovering Biotech Startups, we're looking at San Francisco's MedaRed!
In the newest edition of Discovering Biotech Startups, we're taking a look at Cambridge's Praxis Precision Medicines. Check it out!
The latest edition of Discovering Biotech Startups is looking at San Diego's Virogenics. Check it out!
In this edition of Discovering Biotech Startups, we're looking at the emerging California stealth biotech, Vitalex Biosciences
The newest edition of Sponsor Atlas: Discovering Biotech Startups takes a look at San Francisco's stealth biotech, Deciduous Therapeutics
The newest edition of Sponsor Atlas: Discovering Biotech Startups takes a look at Menlo Park's stealth biotech, Ignite Biosciences
The first edition of Sponsor Atlas: Discovering Biotech Startups takes a look at Pittsburgh's stealth biotech, BlueSphere Bio
(10/05/2015) There isn’t much out there about California’s newest biotech company, but here are a few clues to set you on your way.
(09/28/2014) With Coherus Biosciences’ $86 Million IPO announced last week, we wanted to take a closer look at the companies that stand to benefit the most from the upcoming injection of capital.